• Channels
    • All News
    • Premium Content
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Af­ter 2 de­lays, Zo­genix nabs FDA ap­proval for epilep­sy drug, sets price at 3X its GW Phar­ma com­peti­tor

3 years ago
Pharma
FDA+

Ab­b­Vie’s first post-merg­er Al­ler­gan drug pitch strikes out with the FDA as reg­u­la­tors turn thumbs down on Lu­cen­tis chal­lenger

3 years ago
FDA+

Re­lay and iTeos join IPO del­uge while Ak­ou­os and Fu­sion de­cide they can earn more

3 years ago
Financing

Over a decade ago, a dis­as­trous tri­al killed re­search on a po­ten­tial im­munother­a­py. Can a Re­gen­eron bis­pe­cif­ic re­vive it?

3 years ago
R&D

Sang­amo splits the R from the D in a re­or­ga­ni­za­tion — and bids chief farewell

3 years ago
People
R&D

In an un­ex­pect­ed twist, CSL buys world­wide rights to uniQure's PhI­II he­mo­phil­ia B gene ther­a­py in $2B-plus deal

3 years ago
Deals
Cell/Gene Tx

Ac­celeron promised they had great da­ta on so­tater­cept in late Jan­u­ary. But was it good enough to jus­ti­fy a dou­bling of the stock price?

3 years ago
R&D

Is it re­al­ly over? La Jol­la signs ac­qui­si­tion with Tetraphase af­ter out­bid­ding Acel­Rx, Melin­ta

3 years ago
Deals

Burned by Alzheimer’s fail­ures, a cau­tious Mer­ck turns to a start­up biotech for some pre­clin­i­cal neu­ro pro­grams

3 years ago
Deals
R&D

UK Supreme Court strikes down Re­gen­eron patents, open­ing door for Kymab

3 years ago
Pharma

With its cam­pus ex­pand­ing as gene ther­a­py booms, Alde­vron brings in a top ex­ec from a medtech gi­ant to steer the course

3 years ago
People
Cell/Gene Tx

My­ovant read­ies NDA #3 as re­l­u­golix sails to its 5th pos­i­tive PhI­II — this time in en­dometrio­sis

3 years ago
R&D
FDA+

Daniel O’Day snatch­es an­oth­er I/O com­pa­ny, buy­ing half of a pi­o­neer­ing can­cer drug dis­cov­er­er's biotech

3 years ago
People
Deals

Sanofi wants to earn the rep for be­ing the hare in drug R&D. But that darn tor­toise keeps stick­ing its head out

3 years ago
R&D

Sanofi bets $425M cash on a trans­for­ma­tion-style next-gen vac­cine deal — as the Big Phar­ma team makes a point

3 years ago
Deals

Roche’s an­ti-TIG­IT drug shows ze­ro re­sponse as monother­a­py — but da­ta back ef­fect for lung can­cer sub­set

3 years ago
R&D

Mer­ck ad­vances along a broad PhI­II front, aimed at carv­ing up Pfiz­er’s top-sell­ing vac­cine fran­chise. Could an am­bush lay in wait?

3 years ago
R&D

Cell and gene ther­a­py 2.0 dom­i­nates lat­est round of biotech IPOs in scram­ble for a $300M-plus Nas­daq wind­fall

3 years ago
Financing
Cell/Gene Tx

Covid-19 roundup: In fifth open let­ter, Daniel O’Day touts in­halant remde­sivir, promis­es 2M dos­es by year's end; Mer­ck’s an­tivi­ral moves in­to PhII

3 years ago
Coronavirus

Promi­nent Har­vard pro­fes­sor in the hunt for $100M to back his an­ti-ag­ing play

3 years ago
People
Financing

Ab­b­Vie sweeps out ex­per­i­men­tal gas­tro drugs in a post-merg­er pipeline cleanup. And they can like­ly be yours for the right price

3 years ago
Deals
R&D

Covid-19 roundup: One Chi­nese biotech en­ters clin­ic, an­oth­er eyes fall com­ple­tion, a third shoots for 2021 — while the Warp Speed gen­er­al re­mains Sino-skep­tic

3 years ago
Coronavirus

'A turn­ing point for the field': 4 years af­ter Seres fail­ure, Finch posts pos­i­tive mi­cro­bio­me da­ta

3 years ago
R&D

One of Roche’s spot­light PhI­II can­cer drug hope­fuls stum­bles in a key tri­al, with hit-and-miss re­sults

3 years ago
R&D
First page Previous page 156157158159160161162 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Content
  • Don't Miss
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints Company 2023

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
Endpoints News

Log in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET